U
NWBO

UBS’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

UBS’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$54K Buy
10,800
+2,900
+37% +$17.8K ﹤0.01% 6740
2014
Q2 		$53K Sell
7,900
-12,400
-61% -$78.9K ﹤0.01% 6793
2014
Q1 		$147K Buy
20,300
+800
+4% +$4.74K ﹤0.01% 5542
2013
Q4 		$74K Buy
+19,500
New +$75.5K ﹤0.01% 6450

Other funds holding NWBO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS's NWBO Position: Q3 2014 in Review

UBS reduced its Northwest Biotherapeutics, Inc. Common stock (NWBO) stake by 63% in Q3 2014, selling an estimated $193K and leaving 18,428 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #6097.

UBS first reported a position in NWBO in Q2 2013 and has held it in 6 quarters since. The position peaked at $981K in Q1 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

  • UBS held 18,428 shares of Northwest Biotherapeutics, Inc. Common stock worth $92K as of Q3 2014.
  • UBS sold 31,469 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $193K.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6097 holding.
  • UBS first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Northwest Biotherapeutics, Inc. Common stock position peaked at $981K in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.